Read the latest insights and research related to graft-versus-host disease (GVHD). GVHD is a complication post-transplant where the donor's immune cells attack the recipient's tissues.
Researchers believe treatment with an antibacterial enzyme specific to Enterococcus faecalis may provide prophylaxis against acute graft-versus-host disease (aGVHD).
Findings from the REACH4 clinical trial demonstrate the safety and efficacy of ruxolitinib in pediatric cases of treatment-naïve or steroid-refractory acute graft-versus-host disease (aGVHD).